Inhibiting glucagon release: It reduces the secretion of glucagon, a hormone that increases blood sugar levels
A new Ozempic-like weight loss medication (i.e., GLP-1 receptor agonist) has been found safe and effective for obesity or overweight treatment
A separate study following participants from the STEP 1 clinical trial found that weight, waist circumference and cardiometabolic risk factors largely returned toward baseline levels within 12 months of stopping the medication
Bacterial translocation (BT) in cirrhosis
References [1] An JH, Kim YJ, Kim KJ, et al
Looking for functional ingredients like vitamins or electrolytes reaches ~13% among GLP-1 users, and roughly 24% of Adults selected "None of these" on the functional-ingredients occasion, indicating genuine white space